This paper deals with the problem of singular linear quadratic performance with the worst-disturbance rejection for descriptor systems. Under the conditions we give, the worst-disturbance and the optimal control-state...This paper deals with the problem of singular linear quadratic performance with the worst-disturbance rejection for descriptor systems. Under the conditions we give, the worst-disturbance and the optimal control-state pair are unique respectively, the optimal control can be synthesized as state feedback and the closed-loop system is regular, stable and impulse-free.展开更多
This paper proposes a delay-dependent guaranteed cost control scheme for engine idle speed control (ISC) with induction-to-torque delay and external load disturbance. An augmented linearization model of engine at idle...This paper proposes a delay-dependent guaranteed cost control scheme for engine idle speed control (ISC) with induction-to-torque delay and external load disturbance. An augmented linearization model of engine at idle speed operating mode was developed based on physical principle and experiment data. To provide a compromise between disturbance rejection and other performance requirements of ISC, a multi-objective cost function upper bound was given, which can help us to take into account the fuel economy and disturbance rejection performance together in ISC. Poles constraint was added to the closed-loop system to guarantee convergence rates of state. The whole optimization solution to ISC can be solved under the framework of LMI. A commercial engine model was utilized to assess the performance of the controller. Simulation results on this model show us that designed controller can achieve desired performance.展开更多
目的评价他克莫司常释胶囊与缓释胶囊预防肝移植术后排斥反应的成本-效果。方法选取首都医科大学附属北京友谊医院肝移植门诊2016年1月1日至2023年6月30日收治的肝移植术后患者1520例。其中,1031例患者术后口服常释胶囊,489例患者口服...目的评价他克莫司常释胶囊与缓释胶囊预防肝移植术后排斥反应的成本-效果。方法选取首都医科大学附属北京友谊医院肝移植门诊2016年1月1日至2023年6月30日收治的肝移植术后患者1520例。其中,1031例患者术后口服常释胶囊,489例患者口服缓释胶囊,并在此基础上加用吗替麦考酚酯胶囊(用法用量相同)行免疫抑制治疗。利用TreeAge Pro 2021软件构建Markov模型,研究时限设为30年。以我国医疗卫生体系视角收集成本(直接医疗成本)及效果参数,对缓释胶囊和常释胶囊预防肝移植术后排斥反应的成本-效果进行分析,并通过单因素敏感性分析和概率敏感性分析验证模型。结果与常释胶囊比较,缓释胶囊的增量成本-效果比(ICER)为159357.86元/质量调整生命年(QALY),小于意愿支付阈值(25.7094万元)。缓释胶囊的价格、贴现率和常释胶囊的价格对模型结果影响较大。肝移植术后30年,缓释胶囊具有成本-效果的概率为63.72%。结论肝移植术后30年时限内,与常释胶囊比较,缓释胶囊预防肝移植术后排斥反应更有药物经济学优势。展开更多
基金This work was supported by Natural Science Foundation of Shandong Province (No. Y2004A05, Y2004A07)Science Technology Planning Project of Shandong Provincial Education Department(No. J05P51) and Science Research Foundation of Shandong Economic University
文摘This paper deals with the problem of singular linear quadratic performance with the worst-disturbance rejection for descriptor systems. Under the conditions we give, the worst-disturbance and the optimal control-state pair are unique respectively, the optimal control can be synthesized as state feedback and the closed-loop system is regular, stable and impulse-free.
文摘This paper proposes a delay-dependent guaranteed cost control scheme for engine idle speed control (ISC) with induction-to-torque delay and external load disturbance. An augmented linearization model of engine at idle speed operating mode was developed based on physical principle and experiment data. To provide a compromise between disturbance rejection and other performance requirements of ISC, a multi-objective cost function upper bound was given, which can help us to take into account the fuel economy and disturbance rejection performance together in ISC. Poles constraint was added to the closed-loop system to guarantee convergence rates of state. The whole optimization solution to ISC can be solved under the framework of LMI. A commercial engine model was utilized to assess the performance of the controller. Simulation results on this model show us that designed controller can achieve desired performance.
文摘目的评价他克莫司常释胶囊与缓释胶囊预防肝移植术后排斥反应的成本-效果。方法选取首都医科大学附属北京友谊医院肝移植门诊2016年1月1日至2023年6月30日收治的肝移植术后患者1520例。其中,1031例患者术后口服常释胶囊,489例患者口服缓释胶囊,并在此基础上加用吗替麦考酚酯胶囊(用法用量相同)行免疫抑制治疗。利用TreeAge Pro 2021软件构建Markov模型,研究时限设为30年。以我国医疗卫生体系视角收集成本(直接医疗成本)及效果参数,对缓释胶囊和常释胶囊预防肝移植术后排斥反应的成本-效果进行分析,并通过单因素敏感性分析和概率敏感性分析验证模型。结果与常释胶囊比较,缓释胶囊的增量成本-效果比(ICER)为159357.86元/质量调整生命年(QALY),小于意愿支付阈值(25.7094万元)。缓释胶囊的价格、贴现率和常释胶囊的价格对模型结果影响较大。肝移植术后30年,缓释胶囊具有成本-效果的概率为63.72%。结论肝移植术后30年时限内,与常释胶囊比较,缓释胶囊预防肝移植术后排斥反应更有药物经济学优势。
